Literature DB >> 1878883

Sulfation of some chemically-modified heparins. Formation of a 3-sulfate analog of heparin.

R N Rej1, K G Ludwig-Baxter, A S Perlin.   

Abstract

A modified form of heparin containing residues of nonsulfated alpha-L-idopyranosyluronic acid (7) in place of the normal 2-sulfate (1) was sulfated with sulfur trioxide-trimethylamine in dimethylformamide at 0 and 25 degrees. Examination of the reaction products by n.m.r. spectroscopy showed that sulfation occurred selectively at C-3 of residue 7, to give a new polymer that may be described as a 3-sulfate analog of heparin. A slower substitution reaction led subsequently to sulfation at C-3 of 2-deoxy-2-sulfamino-alpha-D-glucopyranosyl 6-sulfate residues (2), although this was accompanied by partial N-desulfation of 2. An analogous pattern of O-sulfation-N-desulfation was observed for the residues of 2 in two other modified heparins, one containing residues of 2,3-anhydro-alpha-L-gulopyranosyluronic acid and the other residues of alpha-L-galactopyranosyluronic acid, in place of residues of 1. The galacto diastereomer exhibited relatively low regioselectivity, as it was found to be sulfated at C-2 or C-2.3, or both. Selective resulfation of free amino groups gave the products that were examined for anticoagulant activity and susceptibility to enzymolysis by heparinase. Antithrombin-binding affinity measurements were also carried out. Although none of the materials had significant anti-Xa activity, nor were they affected by heparinase, their patterns of binding to antithrombinagarose were not dissimilar to that of heparin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1878883     DOI: 10.1016/0008-6215(91)80130-f

Source DB:  PubMed          Journal:  Carbohydr Res        ISSN: 0008-6215            Impact factor:   2.104


  8 in total

Review 1.  Microbial adherence to and invasion through proteoglycans.

Authors:  K S Rostand; J D Esko
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

2.  Factor h and properdin recognize different epitopes on renal tubular epithelial heparan sulfate.

Authors:  Azadeh Zaferani; Romain R Vivès; Pieter van der Pol; Gerjan J Navis; Mohamed R Daha; Cees van Kooten; Hugues Lortat-Jacob; Marc A Seelen; Jacob van den Born
Journal:  J Biol Chem       Date:  2012-07-19       Impact factor: 5.157

Review 3.  Engineering of routes to heparin and related polysaccharides.

Authors:  Ujjwal Bhaskar; Eric Sterner; Anne Marie Hickey; Akihiro Onishi; Fuming Zhang; Jonathan S Dordick; Robert J Linhardt
Journal:  Appl Microbiol Biotechnol       Date:  2011-11-03       Impact factor: 4.813

Review 4.  High-field NMR as a technique for the determination of polysaccharide structures.

Authors:  B Mulloy
Journal:  Mol Biotechnol       Date:  1996-12       Impact factor: 2.695

5.  Identification of tubular heparan sulfate as a docking platform for the alternative complement component properdin in proteinuric renal disease.

Authors:  Azadeh Zaferani; Romain R Vivès; Pieter van der Pol; Jelleke J Hakvoort; Gerjan J Navis; Harry van Goor; Mohamed R Daha; Hugues Lortat-Jacob; Marc A Seelen; Jacob van den Born
Journal:  J Biol Chem       Date:  2010-12-06       Impact factor: 5.157

Review 6.  Heparan sulfate and heparin interactions with proteins.

Authors:  Maria C Z Meneghetti; Ashley J Hughes; Timothy R Rudd; Helena B Nader; Andrew K Powell; Edwin A Yates; Marcelo A Lima
Journal:  J R Soc Interface       Date:  2015-09-06       Impact factor: 4.118

7.  Orthogonal analytical approaches to detect potential contaminants in heparin.

Authors:  Marco Guerrini; Zhenqing Zhang; Zachary Shriver; Annamaria Naggi; Sayaka Masuko; Robert Langer; Benito Casu; Robert J Linhardt; Giangiacomo Torri; Ram Sasisekharan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-23       Impact factor: 11.205

8.  MASP-2 Is a Heparin-Binding Protease; Identification of Blocking Oligosaccharides.

Authors:  Ditmer T Talsma; Felix Poppelaars; Wendy Dam; Anita H Meter-Arkema; Romain R Vivès; Peter Gál; Geert-Jan Boons; Pradeep Chopra; Annamaria Naggi; Marc A Seelen; Stephan P Berger; Mohamed R Daha; Coen A Stegeman; Jacob van den Born
Journal:  Front Immunol       Date:  2020-04-28       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.